Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide
- 11 November 2012
- journal article
- review article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 36 (3) , 355-357
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac OutputJAMA, 2012
- Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasiaBlood Coagulation & Fibrinolysis, 2011
- A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)Current Vascular Pharmacology, 2010
- Hereditary hemorrhagic telangiectasia: from molecular biology to patient careJournal of Thrombosis and Haemostasis, 2010
- Hereditary haemorrhagic telangiectasia: a clinical and scientific reviewEuropean Journal of Human Genetics, 2009
- The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasiaThe Laryngoscope, 2009
- Hereditary haemorrhagic telangiectasiaHaemophilia, 2008
- Hormonal and Antihormonal Therapy for Epistaxis in Hereditary Hemorrhagic TelangiectasiaThe Laryngoscope, 2004
- Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.2002
- Efficacy of Unusually High Doses of Tranexamic Acid for the Treatment of Epistaxis in Hereditary Hemorrhagic TelangiectasiaNew England Journal of Medicine, 2001